» Test Menu » Chromosome Analysis Leukemic Peripheral Blood (Oncology) Client Login | Email | Phone: 1.800.932.2943

Chromosome Analysis Leukemic Peripheral Blood (Oncology)

Test Code


Test Synonyms

Karyotype analysis, leukemic blood




24, 48 and/or 72 hour culture / G-banding

Turnaround Time

5-7 days

Specimen Requirements

5 mL sodium heparin tube
1 mL (newborn blood)
2 mL (percutaneous umbilical blood)
Fixed cytogenetically prepared cells in sterile centrifuge tube with 3:1, Methanol:Acetic Acid. Pellet must be visible for the volume part and the medium part 3:1, Methanol:Acetic Acid.

Specimen Stability
4 to 25°C, specimens (peripheral blood) are stable up to 72 hours
Fixed cell pellets are stable for years when stored at -28°C to 15°C
Storage & Handling

4°C to 25°C during transit, but specimens may be transported on refrigerated gel packs. Do not allow the gel pack to come in contact with the specimen. Do not freeze. Extreme temperatures should be avoided.

Causes for Rejection

Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells

Reference Range

Chromosome count and morphology consistent with normal karyotype


In hematological malignant diseases, recognized recurring chromosomal abnormalities often correlate with particular subtypes of leukemia that have characteristic morphological and clinical features, such as response to therapy. The study of chromosomal abnormalities serves two functions. The first is to assist in diagnosis, thereby providing prognostic information and allowing the selection of therapy; and the second is to identify the sites of consistent rearrangements, providing the precise localization required for the isolation and cloning of DNA from these regions.

Peripheral blood can be used to study the cytogenetics of malignant conditions only if dividing leukemia cells, as in the leukemic stage of lymphoma or in blast crisis leukemia, are present. Blood samples are preferred only in a limited number of leukemias (such as CML and CLL) and lymphomas, respectively.

  1. Barch M. (1991). The ACT Cytogenetic Laboratory Manual. 2nd edition, 395-396.
  2. Dunn B. (2005). The Cytogenetic Symposia. 2nd edition, 13-1.
  3. Kaplan B. (1994). The Cytogenetic Symposia. 8-1.